Marie Bosslett, Assistant Editor

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Targeted therapies are increasingly used earlier in treatment rather than being reserved for severe or refractory cases.

This review of the latest dermatological studies includes insights on vitiligo cultural beliefs, home-based phototherapy, digital search behavior in NSV patients, and more.

Linda Stein Gold, MD, FAAD, shares her thoughts on FDA-approved, once-daily oral icotrokinra for teens and adults with moderate to severe plaque psoriasis, promising biologic-like results, strong safety, and earlier systemic escalation.

A study shows physician counseling boosts safe adherence and curbs misinformation-driven decisions, as pregnant women often stop skin treatments and experience worsened symptoms.

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

Twin experts reveal how dermatology and dentistry team up for facial aesthetics, early lesion detection, and safer care—from lasers to oral screenings.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on the FDA's approval of icotrokinra, phase 3 ADorable-1 data supporting lebrikizumab, the sBLA acceptance of tildrakizumab for PsA, and more.

Renata Block, DMSc, MMS, PA-C, and Jamie Restivo, MPAS, PA-C, explore how hypochlorous acid sprays and sodium hypochlorite washes simplify AD adjunct care, improving adherence, antimicrobial control, and symptom relief.

Molecular NOS2/CCL27 testing outperforms standard biopsy reads for psoriasis versus eczema, reducing diagnostic uncertainty in CHE and speeding targeted treatment.

This review of the latest dermatological studies includes insights on chronic hand eczema patch testing, case reporting, microbiome impact, and more.

New study links acne to higher serum amyloid A1 inflammation, while lipid shifts hint at systemic effects and new clues for scars and severity.

Meta-analysis finds sexual dysfunction common in asthma and AD, with rates hitting 54% in asthma, prompting better screening.

Sun Pharma's tildrakizumab nears psoriatic arthritis approval as FDA accepts a supplemental biologics license application (sBLA), spotlighting IL-23 benefits for active disease.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on deucravacitinib's approval for PsA, AI-based tumor shape analysis in melanoma, QRX003's fast track for Netherton Syndrome, and more.

New case-control study data link tattoo exposure to a higher melanoma risk, prompting fresh scrutiny of ink chemicals and long-term skin safety.

On National Dermatologist Day, EltaMD unveils oil-balancing UV Clear SPF 50, clinically reducing the appearance of blemishes, shine, and pore size. Learn more in this Q&A with Seemal R. Desai, MD, FAAD, and Annie Woo, MD.

On National Skin Barrier Day, dermatologists share barrier-saving tips for gentle cleansing, daily sunscreen, smarter product audits, and retinoid adherence.

A split-face trial finds adding ivermectin to KTP laser modestly boosts rosacea redness reduction and cuts papules/pustules, without extra downtime.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

FDA Fast Track boosts hopes for QRX003 lotion in Netherton Syndrome, with early trials showing rapid skin healing and itch relief.

This review of the latest dermatological studies includes insights on pediatric teledermatology rates pre- and post-COVID, a 10-peptide face serum for skin quality, AI-automated disease scoring, and more.

Needle-free botulinum toxin microjet TDA delivery cuts facial oil up to 40%, refines pores, and boosts confidence without bruising or downtime in acne patients.

A new study reveals gaps in acne management for teens with PCOS; Hispanic patients are less likely to receive spironolactone, COCs, or isotretinoin treatment.

Real-world data show IL-17 biologics rapidly improve special-site psoriasis and quality of life, as researchers identified predictors of PASI75/90 response.

NFBC1966 data from Finland show that hand eczema is associated with poorer self-rated work ability among middle-aged adults, particularly among those with certain risk factors.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on the end of late-stage rocatinlimab OX40 development, FDA priority review of brepocitinib for dermatomyositis, phase 3 trial data of cemiplimab, and more.